1. Skip to Menu
  2. Skip to Content
  3. Skip to Footer

Hepatitis B Serology

Hepatitis B virus (HBV) is a small double stranded DNA virus composed of an outer envelope containing hepatitis B surface antigen (HBsAg) and an inner nucleocapsid consisting of hepatitis B envelope antigen (HBeAg) and hepatitis B core antigen (HBcAg). The viral core also contains a double stranded DNA genome and DNA polymerase.

HBV infection can result in both acute and chronic hepatitis. Approximately 90% of adults who are infected will resolve the infection without permanent organ damage, while 10% become carriers and 6% progress to chronic disease. Infected newborns and children have a much worse outcome. Chronic infection occurs in 90% of infants infected at birth and in 30% of children infected between ages 1 and 5 years.

After exposure to HBV, there is an incubation period ranging from 45 to 180 days, during which the patient will not exhibit symptoms or positive serologic results. Symptoms, if they appear, usually occur within 4 to 6 weeks after exposure. The most common symptoms include nausea, anorexia, malaise and jaundice. The stage of the infection can be monitored with tests for HBV antigens and antibodies.

HBsAg is the first serologic marker, developing between 6 weeks and 6 months following infection, but prior to onset of symptoms. Presence of HBsAg in serum may indicate acute HBV infection, chronic HBV infection, or asymptomatic carrier state. In acute infection, HBsAg usually disappears within 1 to 2 months after onset of symptoms. HBsAg persists in patients with chronic hepatitis. The significance of a positive test for HBsAg is determined by evaluating it in relationship to the presence or absence of the other HBV markers and the clinical presentation and history of the patient.

Antibody to HBsAg (Anti-HBs) becomes detectable several weeks after HBsAg has disappeared. The interval between disappearance of HBsAg and appearance of anti-HBs is known as the window period and may last as long as 6 months. Detection of anti-HBs usually indicates clinical recovery and subsequent immunity to HBV. Anti-HBs may persist after resolution of the infection. Therefore, the detection of anti-HBs does not discriminate between current or previous infection.

The clinical relevance of anti-HBs detection is in establishing complete resolution of the infection and the acquisition of immunity, whether acquired as a result of natural HBV infection or vaccination. Anti-HBs may fall below detectable levels with time.

Successful vaccination results in detectable anti-HBs. Levels of 10 mIU/mL or greater indicate protection against HBV infection. Anti-HBs quantitation is a useful tool to monitor vaccinees who are likely to have a blunted response incuding:

  • Individuals >30 years of age at the time of first vaccination
  • Immunocompromised patients
  • Obese individuals
  • Patients undergoing dialysis
  • Patients with protein losing nephropathies
  • Individuals working in high risk endemic areas.

HBeAg develops one week after HBsAg is detectable, but before symptoms appear. The presence of HBeAg correlates with the level of infectivity; a patient is most likely to transmit the virus when HBeAg is present. HBeAg usually disappears about 3 weeks before HBsAg disappears. Persistence of HBeAg beyond 12 weeks usually indicates progression to a chronic carrier state. Pregnant women who are positive for HbeAg have a high risk (90%) of HBV transmission to the fetus.

Antibody to HBeAg (anti-HBE) is usually detectable between 12 and 16 weeks, when HBeAg disappears. When a patient is positive for HBsAg and anti-HBE, but negative for HBeAg, there is reduced infectivity and a probable likelihood of resolving the infection. Anti-HBe may be detectable in a chronic carrier. The presence of anti-HBe does not imply immunity to HBV.

Antibody to HBcAg (anti-HBc) appears during the first few weeks after infection, shortly after the onset of symptoms and rises to high levels during convalescence. IgM anti-HBc develops in the acute phase of HBV infection, indicating an infection in the past 3 to 6 months. It is detectable during prodromal, acute, and early convalescent phases. IgM anti-HBc may be the only antibody detectable during the window period when HBsAg has disappeared and before anti-HBs becomes detectable. In this situation, it is considered to be a reliable indicator of ongoing infection. Prenatally acquired anti-HBc gradually disappears in the first 2 to 4 months of life.

IgG anti-HBc develops in the late acute phase of infection. It is measured as part of total anti-HBc and may be the only serologic marker remaining following recovery from infection. It is an accurate serological marker of previous HBV infection, as it appears in all patients infected with the hepatitis B virus and may persist in individuals at low titer long after HBV exposure. In some cases, total anti-HBc titers may fall into the undetectable range along with total anti-HBs.

In subclinical asymptomatic hepatitis B virus infection, HBsAg and HBeAg are present for a brief period or may not be detectable and are followed by the appearance of anti-HBc and anti-HBs. In these patients, detection of total anti-HBc and total anti-HBs must be relied on as evidence of previous HBV infection.

Chronic infection is defined as the absence of concurrent hepatitis B core IgM antibody (IgM anti-HBc) and by persistence of HBsAg or HBV DNA for at least 6 months. In chronic hepatitis B infection, HBsAg appears during the incubation phase of the disease and may persist for years and possibly for life. Total anti-HBc also appears during this early phase and rises in titer. The highest titers of total anti-HBc are found in the chronic HBsAg carrier state. All HBsAg-positive persons are considered infectious.

The presence of HBV DNA in the plasma is an accurate indicator of viral replication. HBV DNA levels that persist longer than 8 weeks may indicate progression to chronic HBV infection.













Early HBV infection, asymptomatic




Acute HBV hepatitis





Chronic HBV infection





Chronic HBV hepatitis,replicating



HBV exposure with recovery/immunity

In October 2008, the Centers for Disease Control (CDC) released new guidelines which expand the testing recommendations for chronic hepatitis B (HBV) infections. Although the incidence of new HBV infections has declined due to vaccine availability, there are an estimated 800,000 to 1.4 million people with chronic HBV infections in the U.S. Because the disease can be asymptomatic for years, those with chronic HBV may be unaware of their infection, and are at high risk for late complications of the disease as well as potentially transmitting the virus. There are an estimated 2,000 to 4,000 deaths in the U.S. annually attributed to hepatitis B infection, mostly due to cirrhosis and liver cancer.

Previously, the CDC recommended hepatitis B screening for pregnant women & infants of HBV-infected mothers, household contacts and sex partners of HBV-infected individuals, HIV-infected people, persons born in countries with HBV prevalence >8%, and post-occupational exposure. The new guidelines expand the testing recommendation to include essentially three new groups:

  • Patients receiving cytotoxic or immunosuppressive therapy, including chemotherapy, organ transplant recipients, and those treated for rheumatologic or gastroenterologic disease.
  • People born in geographic regions with HBV prevalence >2%. This includes Eastern Europe, Asia, the Middle East, and Pacific Islands.
  • People with behavioral exposures to HBV, including past or current injection drug users, and men who have sex with men.

The new guidelines also include recommendations for medical management of chronic HBV and are available through www.cdc.gov, MMWR Recommendations and Reports, September 19,2008; Vol. 57 (RR-8).

AddThis Social Bookmark Button

Stay Informed

Amazon Book

Our Sponsors

Login Form

Mobile Applications

iPad mini Horz Vert 300w

Get it for: iPhoneiPad

ClinLab Navigator Information

McAfee SECURE sites help keep you safe from identity theft, credit card fraud, spyware, spam, viruses and online scams
© 2015 ClinLab Navigator, LLC.